Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8415823 | 0.99 | HRH3 (0.62) | HRH3HTR2AHTR2CHTR2BGRM5 | |
| SCHEMBL787356 | 0.89 | HTR2A (0.60) | HRH3HTR2AHTR2CHTR2BGRM5 | |
| SCHEMBL22725996 | 0.88 | AOC3 (0.61) | HRH3HTR2AHTR2CHTR2BGRM5 | |
| SCHEMBL31409498 | 0.86 | HTR2A (0.53) | HRH3HTR2AHTR2CHTR2BMAOA | |
| SCHEMBL3656203 | 0.85 | HRH3 (0.54) | HRH3HTR2AHTR2CHTR2BGRM5 | |
| SCHEMBL3654185 | 0.81 | DRD2 (0.65) | HRH3HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL3650720 | 0.81 | HRH3 (0.53) | HRH3HTR2AHTR2CHTR2BMAOA | |
| SCHEMBL3652365 | 0.81 | STS (0.51) | HRH3HTR2AHTR2CHTR2BMAOA | |
| SCHEMBL21040263 | 0.81 | MAOA (0.61) | HRH3HTR2AHTR2CHTR2BMAOA | |
| SCHEMBL3653206 | 0.81 | DRD2 (0.56) | HRH3HTR2AHTR2CHTR2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011116356-A2 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | HRH3 1018/4885HTR2A 60/4885HTR2C 41/4885 |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | HRH3 1548/4885HTR2A 1656/4885HTR2C 2581/4885 |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | VCAM1, VAPB, ICAM1 | HRH3 1548/4885HTR2A 1656/4885HTR2C 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.